Abbott Diagnostics Looking Beyond FDA Consent Decree In 2002
This article was originally published in The Gray Sheet
Executive Summary
Abbott Labs is forecasting diagnostics sales growth in the "mid to high single-digit" range in 2002, with the final resolution of its consent decree with FDA and a series of planned product launches, including Prism high-throughput automated blood screening system assays